Pernix Therapeutics
Pernix Therapeutics is a publicly traded specialty pharmaceutical company that develops and markets branded and generic prescription products, with a strategic focus on the pediatric patient population. Headquartered in Houston, Texas, the company historically grew through targeted acquisitions of complementary drug franchises.
- Company typePrivate
- Founded1997
- HeadquartersHouston, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Pernix Therapeutics firmographics
Firmographics- Name
- Pernix Therapeutics
- Website
- https://pernixtx.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Pernix Therapeutics is a publicly traded specialty pharmaceutical company that develops and markets branded and generic prescription products, with a strategic focus on the pediatric patient population. Headquartered in Houston, Texas, the company historically grew through targeted acquisitions of complementary drug franchises.
- Ownership category
- akta.pro rank
Pernix Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Pediatric OTC Medicines (HLAIADAL)
Keywords
Where Pernix Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
Pernix Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D
Pernix Therapeutics product offering
Product offeringCore offering
Pernix Therapeutics develops and markets branded and generic pharmaceutical products for the pediatric market. The company has expanded its product portfolio through acquisitions including Cypress Pharmaceutical (2012) and Somaxon Pharmaceuticals (2013).
Differentiator
Problem solved
Functional benefit
Products and services
- Branded and generic pediatric pharmaceutical products Branded and generic pharmaceutical products developed and marketed by Pernix Therapeutics for the pediatric market.
Companies that use Pernix Therapeutics
Customer profileIdeal customer profiles1 record
Pernix Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Pernix Therapeutics competitors and assessment
Company assessmentDirect peers
- Mayne Pharma: Mayne Pharma operates a specialty and generic pharmaceutical portfolio with U.S. commercial presence. Comparable to Pernix for its mix of branded specialty products and small-molecule generics, particularly in women's health and dermatology extensions into pediatrics.
- Neos Therapeutics: Neos Therapeutics developed branded pediatric ADHD and narcolepsy products using novel drug-delivery technology. Highly comparable given pediatric ADHD focus and small-cap specialty pharmaceutical commercial model.
- Lannett Company: Lannett is a U.S. small/mid-cap generic and specialty pharmaceutical manufacturer with broad distribution. Comparable to Pernix's generic portfolio exposure and similar scale of operations.
- ANI Pharmaceuticals: ANI Pharmaceuticals combines specialty branded products with a generic portfolio across therapeutic areas including pediatrics. Comparable due to mix of branded + generic pharmaceuticals and small/mid-cap U.S. commercial operations.
- AYTU BioScience: AYTU BioScience commercializes branded specialty prescription products, including pediatric urology and allergy assets. Comparable because both companies are small-cap, U.S.-based specialty pharma operators focused on niche patient populations with established sales forces.
- Tris Pharma: Tris Pharma is a specialty pharmaceutical company with deep focus on pediatric and ADHD-related products using innovative drug delivery. It is the most direct comparable to Pernix given overlapping pediatric specialty positioning and branded Rx commercialization model.
Broad incumbents
- Zydus Pharmaceuticals USA: Zydus Pharmaceuticals is the U.S. arm of a global generic and specialty pharma group with significant pediatric and prescription generic offerings. A broad incumbent competitor in the generic and pediatric pharmaceutical segments where Pernix operates.
- Endo International: Endo International is a larger diversified specialty and generics pharmaceutical company with branded and generic portfolios. Comparable as a broad incumbent that competes in the same pediatric specialty and generic prescription channels where Pernix operates.
- Upsher-Smith Laboratories: Upsher-Smith is a U.S.-based branded and specialty generics manufacturer with broad therapeutic coverage including women's health. Adjacent incumbent comparable to Pernix's pediatric/generic small-molecule mix.
Regional players
- Medexus Pharmaceuticals: Medexus commercializes specialty products in the U.S. with extensions in Canada, including pediatric-relevant hematology and allergy products. Comparable because of its small-cap, product-acquisitive specialty model similar to Pernix's historical playbook.
Market position
Customer concentration
Pernix Therapeutics social profiles
Digital presencePernix Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pernix Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Pernix Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pernix Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pernix Therapeutics
What does Pernix Therapeutics do?
Pernix Therapeutics develops and markets branded and generic pharmaceutical products for the pediatric market. The company has expanded its product portfolio through acquisitions including Cypress Pharmaceutical (2012) and Somaxon Pharmaceuticals (2013).
Is Pernix Therapeutics a public or private company?
Pernix Therapeutics is a private company. It is classified as public and is currently operating.
When was Pernix Therapeutics founded?
Pernix Therapeutics was founded in 1997. It employs 251 to 500 people.
Where is Pernix Therapeutics based?
Pernix Therapeutics is headquartered in Houston, United States, in the North America region.
Who are Pernix Therapeutics's main competitors?
Direct peers on record are Mayne Pharma, Neos Therapeutics, Lannett Company, ANI Pharmaceuticals, AYTU BioScience and Tris Pharma. Broad incumbents are Zydus Pharmaceuticals USA, Endo International and Upsher-Smith Laboratories. Medexus Pharmaceuticals is listed as a regional player.
Does Pernix Therapeutics have an API?
No public API is recorded for Pernix Therapeutics.
What industry is Pernix Therapeutics in?
Pernix Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 32541 and its SIC code is 2834.